Latest-analyses-Vitrakvi-larotrectinib-reaffirm-powerful-efficacy-tolerability-profile-adult
In an updated analysis on the adult subset of non-central nervous system (CNS) / TRK fusion cancer patients from three larotrectinib clinical trials, a high overall response rate (ORR) of 67% with a median duration of response (mDoR) of 49.3 months was observed as well as an extended progression-free survival (PFS; median of 25.8 months) as assessed by investigators / Post hoc sub-analysis of investigator-assessed ORR, DoR and PFS of patients (n=218) show uniformly high ORRs in patients regardless of prior treatment or performance status; highest response rates observed in patients receiving first-line larotrectinib (81%) ...
Source: Bayer Company News - September 16, 2021 Category: Pharmaceuticals Source Type: news

Bayer-starts-Phase-III-clinical-development-program-OASIS-with-Elinzanetant
Elinzanetant is an innovative non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause (Source: Bayer Company News)
Source: Bayer Company News - August 31, 2021 Category: Pharmaceuticals Source Type: news

New-Data-Finerenone-protection-patients-chronic-kidney-disease-2-diabetes-cardiovascular-events
(Source: Bayer Company News)
Source: Bayer Company News - August 28, 2021 Category: Pharmaceuticals Source Type: news

Bayer-Strong-growth-guidance-upgrade
Group sales increase by 12.9 percent (Fx & portfolio adj.) to 10.854 billion euros – double-digit percentage growth (Fx & portfolio adj.) at all divisions / EBITDA before special items declines by 10.6 percent to 2.577 billion euros, burdened by currency effects of 153 million euros / Crop Science posts strong sales growth, earnings impacted by higher costs and currency effects / Pharmaceuticals reports significant recovery after COVID-19 effects in prior year / Consumer Health continues growth momentum / Core earnings per share rise by 1.3 percent to 1.61 euros / Net income at minus 2.335 billion euros, addi...
Source: Bayer Company News - August 5, 2021 Category: Pharmaceuticals Source Type: news

Bayer-strengthens-drug-discovery-platform-through-acquisition-of-Vividion-Therapeutics
Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform / Vividion’s unique approach identifies previously unknown binding pockets in undruggable targets to generate first-in-class novel compounds in indications of high unmet medical need / Vividion’s technology has already proven its applicability pre-clinically in oncology and immune-related diseases, with potential to expand into additional therapeutic areas / Vividion to operate autonomously and on an arm’s length basis / Purchase price of USD 1.5 billion upfront and up to USD 500 million in success...
Source: Bayer Company News - August 5, 2021 Category: Pharmaceuticals Source Type: news

Bayer-Provides-Update-on-Path-to-Closure-of-Roundup-Litigation
(Source: Bayer Company News)
Source: Bayer Company News - July 29, 2021 Category: Pharmaceuticals Source Type: news

Bayers-new-symptomatic-chronic-heart-failure-treatment-Verquvo-vericiguat-approved-in-EU
Approved for adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous therapy / Studied in a population with a high risk of cardiovascular death or heart failure hospitalization / The sGC-stimulator Verquvo provides a specific approach to managing chronic heart failure following a decompensation event (Source: Bayer Company News)
Source: Bayer Company News - July 21, 2021 Category: Pharmaceuticals Source Type: news

US-FDA-approves-finerenone-treatment-patients-chronic-kidney-disease-associated-2-diabetes
Finerenone is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular outcomes in patients with chronic kidney disease associated with type 2 diabetes / Despite guideline-directed therapies, many patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) still progress to loss of kidney function and are at high risk for cardiovascular events / By blocking MR overactivation, a key driver of CKD progression, finerenone works on a pathway largely unaddressed by existing treatments for CKD in T2D (Source: Bayer Company News)
Source: Bayer Company News - July 9, 2021 Category: Pharmaceuticals Source Type: news

Vericiguat-approved-in-Japan-to-treat-patients-with-chronic-heart-failure
Heart failure affects approximately 1.2 million people in Japan (Source: Bayer Company News)
Source: Bayer Company News - June 23, 2021 Category: Pharmaceuticals Source Type: news

Bayer-submits-regulatory-applications-oncology-treatment-combination-copanlisib-rituximab-US-EU
In the US, Bayer has filed for relapsed indolent B-cell non-Hodgkin’s lymphoma (B-iNHL) / In the EU, Bayer has filed for relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted / Filings based on results from Phase III trial CHRONOS-3 showing a significant improvement in the primary endpoint of progression-free survival for the combination of copanlisib and rituximab in patients with relapsed iNHL (Source: Bayer Company News)
Source: Bayer Company News - June 21, 2021 Category: Pharmaceuticals Source Type: news

Bayer-to-advance-two-first-of-its-kind-cell-and-gene-therapies-for-Parkinsons-disease
Parkinson’s disease is most common neurodegenerative movement disorder / It impacts more than 10 million people worldwide/ No function-restoring therapy is currently available / Bayer is pursuing a two-pronged approach to deliver transformative therapies with one cell and one gene therapy candidate in clinical trials (Source: Bayer Company News)
Source: Bayer Company News - June 8, 2021 Category: Pharmaceuticals Source Type: news

Bayer-acquires-Noria-and-PSMA-Therapeutics-to-expand-portfolio-in-prostate-cancer
Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer (Source: Bayer Company News)
Source: Bayer Company News - June 3, 2021 Category: Pharmaceuticals Source Type: news

Bayer-announces-five-point-plan-to-effectively-address-potential-future-Roundup-claims
(Source: Bayer Company News)
Source: Bayer Company News - May 27, 2021 Category: Pharmaceuticals Source Type: news

Precision-oncology-treatment-Larotrectinib-submitted-for-marketing-authorization-in-China
(Source: Bayer Company News)
Source: Bayer Company News - May 25, 2021 Category: Pharmaceuticals Source Type: news

Positive-CHMP-opinion-for-Bayers-new-symptomatic-chronic-heart-failure-treatment-vericiguat
Vericiguat is being considered for adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy / Vericiguat was studied in a population with a high risk of cardiovascular death or heart failure hospitalization / European Commission decision is expected in the coming months (Source: Bayer Company News)
Source: Bayer Company News - May 21, 2021 Category: Pharmaceuticals Source Type: news

Long-term-Vitrakvi-larotrectinib-confirm-sustained-clinical-benefit-greater-years-patients-TRK
Larotrectinib achieved 75% (95% CI 68-81) overall response rate (ORR) and median duration of response (DoR) of 49.3 months (95% CI 27.3-not estimable [NE]) in expanded integrated dataset of 206 evaluable adults and children with TRK fusion cancer, which occurs when an NTRK gene fuses with another unrelated gene, across 21 different tumor types and regardless of age (range: 0.1-84 years) with longer follow-up at a median follow-up of 22.3 months / In tumor-specific analyses, larotrectinib demonstrated rapid and durable responses, and long disease control, among patients with lung and primary central nervous system (CNS) TRK...
Source: Bayer Company News - May 19, 2021 Category: Pharmaceuticals Source Type: news

Finerenone-potential-reduce-onset-atrial-fibrillation-flutter-patients-chronic-kidney-disease-2
A prespecified exploratory analysis of the FIDELIO-DKD study demonstrates that finerenone may significantly reduce the risk of new onset atrial fibrillation or flutter (AFF) in patients with CKD and T2D versus placebo when added to standard of care / This analysis also concluded that finerenone reduced the risk of kidney or cardiovascular events with no significant difference in the effect of finerenone between patients with and without history of AFF at baseline / Based on the comprehensive finerenone clinical trial program, finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor (MR) a...
Source: Bayer Company News - May 17, 2021 Category: Pharmaceuticals Source Type: news

Bayer-successful-start-to-2021
Good operational performance – sales and earnings negatively impacted by currency of 938 million euros and 337 million euros / Group sales up by 2.8 percent (Fx & portfolio adj.) to 12.328 billion euros / EBITDA before special items down 6.2 percent to 4.118 billion euros due to currency / Strong sales growth at Crop Science (Fx & portfolio adj.) in improved market environment / Sales at Pharmaceuticals (Fx & portfolio adj.) at prior-year level / Consumer Health ahead of competition with continuous good performance / Net income advances by 40.3 percent to 2.089 billion euros / Core earnings per share decl...
Source: Bayer Company News - May 12, 2021 Category: Pharmaceuticals Source Type: news

Bayers-finerenone-meets-primary-endpoint-Phase-III-FIGARO-DKD-cardiovascular-outcomes-study-patients
Finerenone significantly reduced the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care / Following the FIDELIO-DKD study, FIGARO-DKD is the second positive Phase III study within the finerenone study program in chronic kidney disease (CKD) and type 2 diabetes (T2D) to meet its primary endpoint / Patients with CKD and T2D are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Based on the comprehensive finerenone clinical trial program, finerenone is the first investigational non-steroid...
Source: Bayer Company News - May 10, 2021 Category: Pharmaceuticals Source Type: news

Were-optimistic-for-the-future
Stable operational development in fiscal 2020 despite the COVID-19 pandemic / Dividend of 2.00 euros per share proposed / Early indications of a successful start to 2021 / Board of Management regards Bayer as better positioned than almost any other company to realize the long-term innovation potential of the bio-revolution / Stockholders to elect two new Supervisory Board members (Source: Bayer Company News)
Source: Bayer Company News - April 27, 2021 Category: Pharmaceuticals Source Type: news

Combination-copanlisib-rituximab-significantly-increases-progression-free-survival-patients-relapsed
Copanlisib is the first and only PI3K inhibitor to demonstrate broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to rituximab and placebo / Phase III trial CHRONOS-3 showed the combination of copanlisib and rituximab resulted in a 48% reduction in the risk of disease progression or death in patients with iNHL / The strong reduction in risk of progression or death was observed across all prespecified iNHL subtypes / The adverse event (AE) profile of the copanlisib and rituximab combination was manageable and generally consistent with pre...
Source: Bayer Company News - April 10, 2021 Category: Pharmaceuticals Source Type: news

Bayer-receives-approval-for-Vitrakvi-in-Japan
Precision oncology treatment Vitrakvi™ (larotrectinib) approved for the treatment of NTRK fusion-positive advanced or recurrent solid tumors / In clinical studies, larotrectinib demonstrated high response rates and durable responses in adults and children with TRK fusion cancer, including responses and a high disease control rate in primary central nervous system (CNS) tumors / The Japanese marketing authorization of Vitrakvi follows the approval of the expanded use of FoundationOne®CDx, a comprehensive genomic profiling (CGP) test, in Japan for use as a companion diagnostic (CDx) to identify patients with TRK fu...
Source: Bayer Company News - March 23, 2021 Category: Pharmaceuticals Source Type: news

Bayer-to-further-strengthen-expertise-and-international-profile-of-its-Supervisory-Board
Fei-Fei Li and Alberto Weisser proposed as successors to Johanna Faber and Prof. Dr. Wolfgang Plischke / Supervisory Board compensation to be adjusted (Source: Bayer Company News)
Source: Bayer Company News - March 12, 2021 Category: Pharmaceuticals Source Type: news

Bayer-expects-dynamic-growth-higher-profitability-coming-years-accelerating-transformation
Crop Science: Clear innovation leader in its industry – expected sales and earnings growth above market / Pharmaceuticals: Further growth planned through 2023, new products expected to largely offset the effect of patent expirations – position in cell and gene therapy to be expanded / Consumer Health: Moved from industry underperformer to outperformer – further sales and earnings improvements planned / Core earnings per share anticipated to increase to 7.00 to 7.50 euros by 2024 / Further operational improvements to raise free cash flow to 5 billion euros by 2024 / Bayer in an excellent position to benefi...
Source: Bayer Company News - March 10, 2021 Category: Pharmaceuticals Source Type: news

Bayer-delivers-robust-performance-despite-pandemic-foundation-laid-for-future-growth
Group sales at 41.400 billion euros, impacted by negative currency effects of 1.941 billion euros (Fx & portfolio adj. plus 0.6 percent) / EBITDA before special items level with prior year at 11.461 billion euros (minus 0.1 percent) – currency effects offset by stringent cost management / Crop Science and Pharmaceuticals report stable operational business, Consumer Health sees strong growth / Core earnings per share at 6.39 euros (plus 0.2 percent) / Earnings per share at minus 10.68 euros (2019: plus 4.17 euros), impacted by litigation provisions and impairments / Net financial debt improves by 11.8 percent to 3...
Source: Bayer Company News - February 25, 2021 Category: Pharmaceuticals Source Type: news

Bayer-Divest-Environmental-Science-Professional-Business-Further-Strengthen-Leadership-Team-Crop
(Source: Bayer Company News)
Source: Bayer Company News - February 24, 2021 Category: Pharmaceuticals Source Type: news

Bayer-submits-finerenone-marketing-authorization-China-treatment-chronic-kidney-disease-2-diabetes
(Source: Bayer Company News)
Source: Bayer Company News - February 9, 2021 Category: Pharmaceuticals Source Type: news

New-presented-ASCO-GU-Cancers-Symposium-robustness-overall-survival-benefit-favorable-safety-profile
New analyses from the Phase III ARAMIS trial further strengthen the overall survival benefit and favorable safety profile of darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Additional data from darolutamide and radium-223 dichloride (Xofigo™) trials demonstrate Bayer’s continued commitment to ongoing prostate cancer research to bring meaningful benefit to the lives of men across different stages of the disease / Expert-led and patient perspectives as well as additional prostate cancer educational resources for media can be found on Bayer’s ASCO GU Vi...
Source: Bayer Company News - February 8, 2021 Category: Pharmaceuticals Source Type: news

Bayer-and-Orion-expand-development-program-for-darolutamide-in-prostate-cancer
Phase III study ARANOTE to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) assessing the novel androgen-receptor antagonist in combination with standard androgen deprivation therapy / Start of patient enrollment expected by the end of Q1 2021 / Study adds to the robust development program for NUBEQA, exploring an opportunity to help even more patients with prostate cancer (Source: Bayer Company News)
Source: Bayer Company News - February 8, 2021 Category: Pharmaceuticals Source Type: news

Bayer-receives-approval-Nubeqa-China-treatment-non-metastatic-castration-resistant-prostate-cancer
(Source: Bayer Company News)
Source: Bayer Company News - February 3, 2021 Category: Pharmaceuticals Source Type: news

Bayer-to-manufacture-mRNA-vaccine-in-Germany
(Source: Bayer Company News)
Source: Bayer Company News - February 1, 2021 Category: Pharmaceuticals Source Type: news

Ukko-secures-USD-million-Series-B-funding-Leaps-Bayer-overcome-allergies-sensitivities
Top industry leaders and venture firms unite behind Ukko’s efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten (Source: Bayer Company News)
Source: Bayer Company News - January 27, 2021 Category: Pharmaceuticals Source Type: news

US-FDA-approves-vericiguat-for-patients-with-symptomatic-chronic-heart-failure
Vericiguat (Verquvo ® ) is the first soluble guanylate cyclase (sGC) stimulator to be approved for the treatment of symptomatic chronic heart failure / Vericiguat works on a pathway not currently targeted by existing heart failure treatments (Source: Bayer Company News)
Source: Bayer Company News - January 20, 2021 Category: Pharmaceuticals Source Type: news

Bayer-transforms-pharma-business-through-breakthrough-innovation-in-healthcare
Emerging leadership in field of cell and gene therapies / Accelerating breakthrough innovation for patients / Innovation in field of digital health solutions to become key pillar of Bayer’s pharmaceutical business empowering patients with Integrated Care offerings / Promising development portfolio with more than 50 projects in clinical development phases (Source: Bayer Company News)
Source: Bayer Company News - January 13, 2021 Category: Pharmaceuticals Source Type: news

US-FDA-grants-priority-review-New-Drug-Application-finerenone-treat-patients-chronic-kidney-disease
(Source: Bayer Company News)
Source: Bayer Company News - January 12, 2021 Category: Pharmaceuticals Source Type: news

Supervisory-Board-Bayer-AG-appoints-Sarena-Lin-Board-Management-Chief-Transformation-Talent-Officer
(Source: Bayer Company News)
Source: Bayer Company News - January 11, 2021 Category: Pharmaceuticals Source Type: news

Bayer-issues-new-senior-bonds-with-a-volume-of-4-billion-euros
Issuance of four tranches with maturities between 4 and 15 years was substantially oversubscribed (Source: Bayer Company News)
Source: Bayer Company News - January 7, 2021 Category: Pharmaceuticals Source Type: news

CureVac-and-Bayer-join-forces-on-COVID-19-vaccine-candidate-CVnCoV
Companies enter into a collaboration and services agreement / Bayer to support CureVac in numerous areas, including development and supply of CVnCoV / CureVac benefits from Bayer ´ s expertise and established infrastructure / Plan to facilitate the supply of several hundred million doses (Source: Bayer Company News)
Source: Bayer Company News - January 7, 2021 Category: Pharmaceuticals Source Type: news

Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news

Bayer-Atara-Biotherapeutics-enter-strategic-collaboration-generation-mesothelin-targeted-CAR-T
Agreement is fundamental element of Bayer’s new Cell & Gene Therapy strategy / Bayer to enter CAR-T cell therapy space and expand oncology development pipeline with groundbreaking technology / Recognizes the leading position of Atara’s technology platform in allogeneic cell therapy / Partnership will focus on the next generation, off-the-shelf T-cell immunotherapy ATA3271 for treatment of high mesothelin-expressing tumors / Atara to receive upfront payment of USD 60 million, and up to a total of USD 610 million for development, regulatory and commercialization milestones, plus tiered royalties up to low dou...
Source: Bayer Company News - December 7, 2020 Category: Pharmaceuticals Source Type: news

Third-quarter-of-2020-
Group sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros / EBITDA before special items falls 21.4 percent to 1.795 billion euros / Substantial decline in sales and earnings at Crop Science, heavily impacted by seasonal and currency effects / Pharmaceuticals business recovering – higher earnings but slightly lower sales / Strong performance at Consumer Health / Net loss of 2.744 billion euros – impairment charges at Crop Science, proceeds from divestment of Animal Health / Core earnings per share decline by 30.2 percent to 0.81 euros / Free cash flow falls by 2.1 percent to 1.237 bill...
Source: Bayer Company News - November 3, 2020 Category: Pharmaceuticals Source Type: news

Rivaroxaban-application-submitted-US-FDA-indication-patients-after-lower-extremity-revascularization
FDA submission based on results from Phase III VOYAGER PAD study which showed a significant reduction in the primary efficacy endpoint in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) / There is currently no Class I Guideline recommended treatment for this patient population / It is estimated that as many as 20 million Americans are living with PAD (Source: Bayer Company News)
Source: Bayer Company News - October 26, 2020 Category: Pharmaceuticals Source Type: news

Bayer-acquires-Asklepios-BioPharmaceutical-to-broaden-innovation-base-in-cell-and-gene-therapy
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need / AskBio's industry leading AAV-based gene therapy platform already yielding commercial and clinical stage assets with potential of helping larger patient populations / Portfolio includes investigational pre-clinical and clinical stage development candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases such as therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure, ...
Source: Bayer Company News - October 26, 2020 Category: Pharmaceuticals Source Type: news

New England Journal of Medicine publishes final overall survival data for Nubeqa ™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancer (for specialized target groups only)
Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety profile at final analysis remains consistent with the earlier analysis; overall, the rate of adverse events was comparable to ADT alone (Source: Bayer Company News)
Source: Bayer Company News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases
Drug Discovery partnership and equity investment led by Leaps by Bayer in Series D financing round / Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster (Source: Bayer Company News)
Source: Bayer Company News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Bayer submits vericiguat for marketing authorization in China for the treatment of chronic heart failure (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - August 28, 2020 Category: Pharmaceuticals Source Type: news

Bayer and Northpond Ventures lead USD 55 million Series A financing round for Triumvira Immunologics
Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments / Triumvira’s T-cell therapies have transformative potential as a new type of cancer treatment that uses the immune system to fight cancer / Pipeline includes four therapeutic candidates for both autologous and allogeneic T-cell immuno therapies for treatment of liquid and solid tumors (Source: Bayer Company News)
Source: Bayer Company News - August 27, 2020 Category: Pharmaceuticals Source Type: news

Bayer receives approval for Xofigo ® in China (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - August 27, 2020 Category: Pharmaceuticals Source Type: news

Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areas
Deal value up to USD 98 million including increased equity stake and joint development of digital health platform / Collaboration reinforces Bayer’s commitment to developing integrated care solutions for patients (Source: Bayer Company News)
Source: Bayer Company News - August 24, 2020 Category: Pharmaceuticals Source Type: news

Science Based Targets initiative endorses climate protection targets of Bayer AG
Important step in Bayer becoming climate-neutral by 2030 / Targets integral to Board of Management remuneration (Source: Bayer Company News)
Source: Bayer Company News - August 21, 2020 Category: Pharmaceuticals Source Type: news